The sleep problem plaguing over a billion people: Lemai Medical pioneers a groundbreaking therapy to end the struggle.

Obstructive sleep apnea (OSA) has become a sleep disorder affecting over one billion people

Clinically, this disease is primarily characterized by recurrent episodes of apnea and hypopnea during sleep. In addition to causing or exacerbating respiratory failure, it is alsoRisk factors for mental disorders, metabolic diseases, and cardiovascular and cerebro, is a systemic disease. CurrentlyExisting guidelines have identified OSA as a serious social issue

However, this disease, which afflicts over a billion patients, had previously faced significant

CPAP is considered the preferred treatment with proven efficacy, yet over half of patients eventually discontinue therapy due to issues such as discomfort from the mask, noise from airflow, and restricted movement during sleep. For children, long-term use of positive pressure ventilator masks and straps can lead to facial compression, resulting in serious effects like facial indent

Although clinical practice emphasizes interventions targeting the etiological structure itself, technological limitations have delayed the emergence of relevant innovative therapies in the market.

It is precisely this unmet clinical need that has given rise toSomnics (SomnicsThe entrepreneurial journey. Founded in 2010, this global healthcare technology enterpriseLeveraging the innovative biomechanical design of intraoral negative pressure therapy, it redefines the treatment pathway for OSA

The inception of Lemai Medical originated from the personal experience of its founder, Chen Zhongzhu

Years ago, after being diagnosed with OSA, Chen Zhongzhu tried various treatments, but ultimately, the only options left for him were undergoing surgery on his jaws and throat or relying on a breathing machine for life. Deeply affected by the plight of patients and the unmet clinical needs, he was determined to break away from the conventional approach of using CPAP to maintain airway openness with high-pressure airflow and instead innovate new

Founder of Lemai Medical, Chen Zhongzhu

During his tenure in medical device research and development at Stanford University, Chen Zhongzhu began to contemplate the possibility of moving away from the traditional models of masks and positive pressure ventilation, instead maintaining airway patency in a way that more closely aligns with the body's natural state. Years of deep engagement in the medical engineering field led him to the idea of intraoral negative pressure. He firmly believed that as long as a product is anatomically compatible, physiologically logical, and offers a better user experience, it holds significant value for further research and development

And this became the prototype for the development of Lemai Medical's iNAP.

iNAP Product

Generally speaking, pathological sleep apnea is caused by abnormal anatomical structure of the upper airway, decreased muscle tone in the upper airway, and abnormal respiratory regulation by the respiratory center. The core pathological mechanisms include skeletal structural reasons, soft tissue reasons, and neuromuscular regulation

Laimed Medical precisely targets the pathological mechanism of OSA, addressing the treatment challenge from its anatomical root

OSA Pathological Mechanism

iNAP maintains an open upper airway by applying negative pressure intraorally to pull the tongue, soft palate, and surrounding soft tissues forward, reducing reliance on mouth breathing and restoring natural nasal breathing. The treatment process aligns seamlessly with the natural logic of human respiration—it does not alter lung pressure differentials or disrupt sleep rhythms, significantly reducing physiological burden on the patient. Leveraging its non-invasive nature, it also enhances acceptance and compliance, precisely aligning with the global medical trend toward "non-invasiveness, personalization, and precision."

It is worth mentioning that to achieve personalized negative pressure therapy and maximize treatment efficacy, Lemai Medical has established a multi-port, multi-platform data management and service system

InPatient Side, the developed mini-program is compatible with iOS, Android, and HarmonyOS applications. It can directly interface with therapeutic devices, uploading critical data such as treatment pressure, usage duration, and airway seal integrity to the cloud in real time. This allows both medical professionals and patients to intuitively monitor the device's usage dynamics. InDoctor SideThe dedicated management device deployed within the hospital can simultaneously control 5-20 therapy machines, enabling centralized management of multiple patients. Once patient data is synchronized to the hospital’s dedicated cloud platform, doctors can monitor patient status and feedback in real time and optimize treatment plans promptly. The cloud platform can also automatically analyze the data to determine whether adjustments to therapeutic pressure or replacement of oral interface accessories are needed, thereby assisting clinicians in decision-making.

Today, Lem Medical continues to expand the range of physiological data that its devices can monitor. Not only has it incorporated blood oxygen monitoring into the system, but it also plans to extend monitoring to include brain waves and other dimensions. By leveraging more comprehensive physiological data, such as breathing patterns and sleep architecture, the company aims to more accurately track patients' conditions and achieve full-cycle closed-loop management. Ultimately, this approach enables the development of truly personalized treatment plans for each patient, enhancing the efficiency of medical care.

From the finalization of the iNAP product in 2016, to Lemai Medical advancing multi-country, multi-center trials in Europe and the United States, and then to successively obtaining...TFDA, FDA, and NMPA, among others, for market access in 30+ countries/regions. Within this, rigorous scientific research and the accumulation of comprehensive clinical data have always been the foundation upon which Lumen Medical stands in the industry

As of 2023, iNAP technology has secured 183 authorized patents worldwide, including 161 invention patents. Related research findings have been published in over 45 core journals

Efficacy Data

In addition, iNAP has already served over ten thousand patients worldwide. Clinical data shows that using iNAPPatient compliance exceeds 75, significantly higher than the average CPAP level, withAHI Index(Apnea-Hypopnea Index) achieved43 times/hour decreased to 0.2, with an average reduction99.5%，Blood oxygen concentration increased by nearly , products and services have been validated

Therapeutic Principles and Clinical Efficacy

Although Lemai Medical has accumulated scientific research achievements and clinical data, the company has not stopped there. Instead, it recognizes that the Chinese market requires more local data to build doctors' understanding of this innovative intraoral negative pressure therapy.

Therefore, targeting the Chinese market, Lemai Medical has focused on "clinical pilot programs, collaborative data building, and exploration of application pathways" as its core strategy, precisely directing efforts at the level of clinical collaboration. It has already partneredShanghai Eye, Ear, Nose and Throat HospitalConducting an intervention trial for mouth breathing in childrenBeijing's Top-Tier NeurologyCollaborate to explore sleep-breathing intervention strategies for patients with mild cognitive impairment, alongside experts in the fieldTop domesticResearch on the Population with Combined Hypertension and OSA

The systematic layout has not only enabled iNAP to accumulate local clinical data, accelerating its implementation in China and laying the groundwork for commercial insurance partnerships and regional replication, but it has also provided solid support for the company's subsequent business expansion.

Laimed MedicalClinical networks have now extended to Hong Kong and Macau.，And continuously plan to advance new phase research in Germany, Denmark, the United States, and other. The company's research focus has also expanded beyond单纯的 OSA treatment toCovering hypertension combined with OSA, pre-Alzheimer's mild cognitive impairment OSA, adolescent OSA, and high-risk occupational OSA, among others.Unmet clinical needs

The sleep respiratory care industry is part of an unmet market for major chronic diseases. According to data from Southwest Securities, the global market size for home ventilators is expected$11.2。

As the world's largest sleep disorder market, China not only boasts a massive patient population and significant unmet clinical needs but also features increasingly standardized regulatory and clinical systems, making it an ideal environment for validating innovative therapies. Furthermore, top-tier hospitals in China possess world-class clinical research capabilities, and the clinical evidence they produce is highly compelling

In the future, Lianmei Medical will adopt a core strategy of "clinical initiatives first, digital support, and authorized agency partnerships." The company aims to establish brand recognition and industry influence through academic breakthroughs, then gradually build commercial channels and after-sales systems. In the short term, the company will complete clinical deployments in Germany, the United States, Hong Kong and Macau (China), and Denmark, deepening research on four key populations: hypertension comorbid with OSA, pre-Alzheimer's mild cognitive impairment with OSA, adolescent OSA, and high-risk occupational OSA. In the medium term, the company will promote the implementation of iNAP and its derivative products in Asia-Pacific countries, accelerate international market expansion, complete the integrated development of digital platforms and product services, and achieve market listing. In the long term, the company will target the global sleep therapy market, aiming to become a leading brand in alternative CPAP solutions